Sabby Management’s Palisade Bio PALI Stock Holding History

Sabby Management’s Portfolio PALI Stock Details PALI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Hold	–	-$157K	–	195
2017 Q2	–	Hold	–	–	–	185
2017 Q1	–	Hold	–	–	–	235

Other funds holding PALI

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sabby Management's PALI Position: Q4 2022 in Review

Sabby Management sold out of Palisade Bio (PALI) in Q4 2022, closing a stake of 595 shares — an estimated $44K sold.

Sabby Management first reported a position in PALI in Q2 2016 and held it in 14 quarters. The position peaked at $2.72M in Q1 2017. 11 funds tracked by Wall St. Rank hold PALI as of Q4 2022.

Sabby Management reported no remaining Palisade Bio position as of Q4 2022 after selling out during the quarter.
Sabby Management sold 595 Palisade Bio shares in Q4 2022, an estimated $44K.
Sabby Management first reported a position in Palisade Bio in Q2 2016 and held it in 14 quarters.
Sabby Management's Palisade Bio position peaked at $2.72M in Q1 2017.
11 funds tracked by Wall St. Rank held Palisade Bio as of Q4 2022.

Based on Sabby Management's 13F filing for Q4 2022, filed 14 Feb 2023.